BDC-4182
- Generic Name
- BDC-4182
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
Phase 1
Recruiting
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT06921837
- Locations
- 🇦🇺
AUS Site 2, Darlinghurst, New South Wales, Australia
🇦🇺AUS Site 1, Birtinya, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath